Report Type: Industry Trends
Report Category: Research Insights
Report Subcategory: Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T)
Price: 2999.00
Date: July 2021

Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T): Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T):
CAR-T is a type of treatment in which a patient's T cells are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer.

Key Players:
A2 Biotherapeutics Inc, AbbVie Inc, AbClon Inc, Adicet Bio Inc, AffyImmune Therapeutics Inc, AGC Biologics SpA, AgenTus Therapeutics Inc, Aleta Biotherapeutics Inc, Allogene Therapeutics Inc, Anixa Biosciences Inc, Appia Bio Inc, Ares Immunotherapy Inc, Arsenal Biosciences Inc, Artiva Biotherapeutics Inc, Atara Biotherapeutics Inc, Atossa Therapeutics Inc, Aucentra Therapeutics Pty Ltd, Aurora BioPharma Inc, Autolus Therapeutics Plc, Avalon GloboCare Corp, Baylor College of Medicine
Beam Therapeutics Inc, Beijing Immunochina Pharmaceuticals Co Ltd, Bellicum Pharmaceuticals Inc, Biocure Technology Inc, bluebird bio Inc, Bristol-Myers Squibb Co
California Institute for Biomedical Research, Caribou Biosciences Inc, Carisma Therapeutics Inc, CARsgen Therapeutics Ltd, Cartesian Therapeutics Inc, Case Comprehensive Cancer Center, Celgene Inc, Celgene KK, CellCure, Cellectis SA, Cellular Biomedicine Group Inc, Celularity Inc, Celyad Oncology, Century Therapeutics Inc, City of Hope, CoImmune Inc, CRISPR Therapeutics AG, Curocell Inc, CytoImmune Therapeutics Inc, CytomX Therapeutics Inc, Duke University, Duke University Medical Center, Elicio Therapeutics Inc, EmendoBio Inc, Endocyte Inc, Eureka Therapeutics Inc, EXUMA Biotech Inc, Fate Therapeutics Inc, Fred Hutchinson Cancer Research Center, Genus Oncology LLC, Gilead Sciences, Green Cross LabCell Corp, H. Lee Moffitt Cancer Center & Research Institute Inc, Hebei Senlang Biotechnology Co Ltd, Helix BioPharma Corp, Humanigen Inc, Humorigin Biotechnology Corp, iCell Gene Therapeutics LLC, Icell Kealex Therapeutics LLC, Immune Onc Therapeutics Inc, Immune Therapeutics Inc, ImmuneCyte Inc, ImmunityBio Inc, Imugene Ltd, Innovative Cellular Therapeutics Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, JW Cayman Therapeutics Co Ltd, Kiromic BioPharma Inc, Kite Pharma EU BV, Kite Pharma Inc, Kuur Therapeutics Ltd, Legend Biotech Corp, Lentigen Technology Inc, Les Laboratoires Servier SAS, Leucid Bio Ltd, Liminatus Pharma LLC, LineaRx Inc, Loyola University Chicago, Luminary Therapeutics Inc, MabVax Therapeutics Holdings Inc, Marizyme Inc, Massachusetts General Hospital, MaxCyte Inc, MedAbome Inc, Medical College of Wisconsin, Meditope Biosciences Inc, Memorial Sloan Kettering Cancer Center, Miltenyi Biotec BV & Co KG, MimiVax LLC, Minerva Biotechnologies Corp, Mitotherapeutix LLC, Monarch Biosciences Inc, Multitude therapeutics Inc, Mustang Bio Inc, Myeloid Therapeutics Inc, Nanjing KAEDI Biotech Inc, National Cancer Institute US, Neomics Pharmaceuticals LLC, Nkarta Inc, Nohla Therapeutics Inc, Noile-Immune Biotech Inc, Novartis AG, Novartis Australia Pty Ltd, Novartis Pharma AG, Novartis Pharma KK, Novartis Pharmaceuticals Canada Inc, Novartis Pharmaceuticals Corp, Novartis Pharmaceuticals UK Ltd, Novartis UK Ltd, Obsidian Therapeutics Inc, OGD2 Pharma SAS, OncoC4 Inc, Oncternal Therapeutics, Orgenesis Inc, Ottawa Hospital Research Institute, Oxford BioMedica Plc, PeproMene Bio Inc, PersonGen Biomedicine Suzhou Co Ltd, Phanes Therapeutics Inc, Phio Pharmaceuticals Corp, Poseida Therapeutics Inc, Precigen Inc, Precision Biosciences Inc, Protheragen Inc, Refuge Biotechnologies Inc, Rejuvenation Technologies Inc, SA Science Inc, Sana Biotechnology Inc, Sandhill Therapeutics Inc, Seattle Children's Hospital, Senti Biosciences Inc, Shanghai SunTerra Biotechnology Ltd, Sorrento Therapeutics Inc, St. Jude Children’s Research Hospital Inc, Stanford University, Stanford University School of Medicine, Synthekine Inc, Takara Bio Inc, Targazyme Inc, Temple University, Tessa Therapeutics Ltd, Timmune Biotech Inc, Tmunity Therapeutics Inc, Triumvira Immunologics Inc, Tychon Bioscience Inc, U.S. Department of Veterans Affairs, U.S. National Institutes of Health, UCLAs Jonsson Comprehensive Cancer Center, UNC Lineberger Comprehensive Cancer Center, University of Alberta, University of California, University of California Los Angeles, University of Colorado Denver, University of Illinois at Urbana-Champaign, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Texas MD Anderson Cancer Center, Vor BioPharma Inc, WindMIL Therapeutics Inc, Wugen Inc, Xenetic Biosciences Inc, Xyphos Biosciences Inc, ZIOPHARM Oncology Inc